跳至主要内容
临床试验/CTRI/2023/11/059873
CTRI/2023/11/059873尚未招募3 期

A Master Protocol to Investigate the Efficacy and Safety of LY3437943Once Weekly in Participants without Type 2 Diabetes who have Obesity orOverweight: A Randomized, Double-Blind, Placebo-Controlled Trial(TRIUMPH-1) - NI

Eli Lilly and Company India Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Have body mass index (BMI) =30.0 kilograms per square meter (kg/m²), or =27.0 kg/m² with at least one of the following: hypertension, dyslipidemia
  • obstructive sleep apnea, or cardiovascular disease
  • 2. History of at least one unsuccessful dietary effort to reduce body weight

排除标准

  • 1. Have a self-reported or documented change in body weight >5 kg (11 pounds) within 90 days.
  • 2. Have taken weight loss drugs, including over-the-counter medications, within 90 days prior to screening.
  • 3. Have a prior or planned surgical treatment for obesity.
  • 4. Have diabetes mellitus.
  • 5. Have family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
  • 6. Have had pancreatitis.

研究者

发起方
Eli Lilly and Company India Pvt Ltd

相似试验